Geron (GERN) Net Cash Flow Growth (5y) (2015 - 2026)
Powered by 
Analysis
Geron (GERN) Net Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17.49% |
| Mar 31, 2026 | -19.13% |
| Dec 31, 2025 | 56.53% |
| Sep 30, 2025 | -57.29% |
| Jun 30, 2025 | -33.60% |
| Mar 31, 2025 | -6.64% |
| Dec 31, 2024 | 35.88% |
| Sep 30, 2024 | -82.76% |
| Jun 30, 2024 | -54.57% |
| Mar 31, 2024 | 102.12% |
| Dec 31, 2023 | 83.01% |
| Sep 30, 2023 | -32.57% |
| Jun 30, 2023 | -47.44% |
| Mar 31, 2023 | 53.93% |
| Dec 31, 2022 | -21.65% |
| Sep 30, 2022 | -45.57% |
| Jun 30, 2022 | -25.52% |
| Mar 31, 2022 | -30.12% |
| Dec 31, 2021 | -3.37% |
| Sep 30, 2021 | -64.91% |